<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561962</url>
  </required_header>
  <id_info>
    <org_study_id>20130314</org_study_id>
    <nct_id>NCT02561962</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in human phase 1 multicenter open label study in subjects with relapsed or
      refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first in human phase 1 multicenter open label study to evaluate the safety and
      tolerability of AMG 224 in subjects with relapsed or refractory multiple myeloma. The study
      will be conducted in 2 parts. Part 1 is the dose-exploration and part 2 is the
      dose-expansion. Study medication will be administered once every 3 weeks by IV.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2015</start_date>
  <completion_date type="Anticipated">March 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of dose limiting toxicities (DLTs), treatment-related, treatment-emergent</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 224</intervention_name>
    <description>AMG 224 will be given on Day 1 once every 3 weeks with dose ranging from 30 mg to 300 mg.</description>
    <arm_group_label>Dose Exploration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Pathologically documented,multiple myeloma relapsed or refractory progressive disease
        after at least 3 lines of therapy for multiple myeloma.

        Prior therapeutic treatment or regimens must include proteasome inhibitors (e.g.
        bortezomib) and immunomodulatory drugs (e.g. lenalidomide).

          -  Willing and able to undergo bone marrow aspirate per protocol (with or without bone
             marrow biopsy per institutional guidelines).

          -  Measurable disease per the IMWG response criteria

          -  Hematological function, as follows, without transfusion support:

          -  Absolute neutrophil count ≥ 1.0 X 10 9/L,

          -  Platelet count ≥ 75 X 109/L (in patients with &lt; 50% of bone marrow nucleated cells
             were plasma cells) or ≥ 50 X 109/L (in patients with ≥ 50% of bone marrow nucleated
             cells were plasma cells) without transfusion or growth factor support

          -  Hemoglobin &gt; 8 g/dL (&gt; 80 g/L)

          -  Adequate renal and hepatic function

          -  Left ventricular ejection fraction (LVEF) &gt; 50%

        Exclusion Criteria:

          -  Currently receiving treatment in another investigational device or drug study, or less
             than 28 days since ending treatment on another investigational device or drug study

          -  Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or
             investigational agent) within 28 days prior to study day 1

          -  Multiple myeloma with IgM subtype

          -  Glucocorticoid therapy (prednisone &gt; 30 mg/day or equivalent) within 7 days prior to
             study day

          -  Autologous stem cell transplant less than 90 days prior to study day 1

          -  POEMS syndrome, Plasma cell leukemia, Waldenstrom's macroglobulinemia or Amyloidosis

          -  Myocardial infarction within 6 months of study day 1, symptomatic congestive heart
             failure (New York Heart Association &gt; class II)

          -  A baseline ECG QTcF &gt; 470 msec
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed Multiple Myeloma</keyword>
  <keyword>Refractory Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

